1965JAMARequires access

Busulfan (Myleran) for Myelocytic Leukemia

J. W. Frost

Open publisher page 0 citations

Abstract

To the Editor:— In your issue of July 19 (193:255, 1965), there is a question in regard to the treatment of chronic myelocytic leukemia. This is answered by Dr. John W. Frost with the unequivocal statement that "Busulfan (Myleran) is the treatment of choice in chronic myelocytic leukemia." Although this may be true, I have seen no report of the results of treatment with Busulfan, which are comparable to the number of cases treated, or the results of treatment, reported as the result of treatment by means of x-ray or radioactive phosphorus. J. H. Lawrence reported on the latter in 1954; Osgood and associates reported on a comparison of x-ray treatment with that of irradiated phosphorus in 1955; also, a report of my treatment has appeared in a relatively small series, published both in Germany and America, in 1961. Until it has been demonstrated by adequate comparisons, it seems

About this research paper

What this paper is about

To the Editor:— In your issue of July 19 (193:255, 1965), there is a question in regard to the treatment of chronic myelocytic leukemia. This is answered by Dr. John W. Frost with the unequivocal statement that "Busulfan (Myleran) is the treatment of choice in chronic myelocytic leukemia." Although this may be true, I have seen no report of the results of treatment with Busulfan, which are comparable to the number of cases treated, or the results of treatment, reported as the result of treatment by means of x-ray or radioactive phosphorus. J. H. Lawrence reported on the latter in 1954; Osgood and associates reported on a comparison of x-ray treatment with that of irradiated phosphorus in 1955; also, a report of my treatment has appeared in a relatively small series, published both in Germany and America, in 1961. Until it has been demonstrated by adequate comparisons, it seems

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To the Editor:— In your issue of July 19 (193:255, 1965), there is a question in regard to the treatment of chronic myelocytic leukemia. This is answered by Dr. John W. Frost with the unequivocal statement that "Busulfan (Myleran) is the treatment of choice in chronic myelocytic leukemia." Although this may be true, I have seen no report of the results of treatment with Busulfan, which are comparable to the number of cases treated, or the results of treatment, reported as the result of treatment by means of x-ray or radioactive phosphorus. J. H. Lawrence reported on the latter in 1954; Osgood and associates reported on a comparison of x-ray treatment with that of irradiated phosphorus in 1955; also, a report of my treatment has appeared in a relatively small series, published both in Germany and America, in 1961. Until it has been demonstrated by adequate comparisons, it seems

Key concepts: Myelocytic leukemia, Busulfan, Medicine, Leukemia, Dermatology, Surgery, Internal medicine, Chemotherapy

Related papers

Back to paper searchBrowse research topicsOriginal source
Busulfan (Myleran) for Myelocytic Leukemia — Research Paper | ScholarLens